Agios Pharmaceuticals (NASDAQ:AGIO) has been given a $90.00 target price by analysts at Canaccord Genuity in a research note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s target price would indicate a potential upside of 60.49% from the company’s previous close.

A number of other brokerages have also recently weighed in on AGIO. SunTrust Banks restated a “buy” rating and set a $80.00 price objective on shares of Agios Pharmaceuticals in a research note on Wednesday, October 4th. J P Morgan Chase & Co restated a “buy” rating and set a $76.00 price objective on shares of Agios Pharmaceuticals in a research note on Monday, September 18th. Royal Bank of Canada began coverage on Agios Pharmaceuticals in a research note on Thursday, September 14th. They set an “outperform” rating and a $78.00 price objective for the company. Credit Suisse Group upped their price objective on Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, November 2nd. Finally, Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Agios Pharmaceuticals has an average rating of “Buy” and a consensus target price of $75.70.

Agios Pharmaceuticals (NASDAQ:AGIO) opened at $56.08 on Tuesday. Agios Pharmaceuticals has a 12-month low of $39.24 and a 12-month high of $72.73.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.78) by $0.19. The firm had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The firm’s quarterly revenue was up 26.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.63) EPS. sell-side analysts predict that Agios Pharmaceuticals will post -6.59 EPS for the current year.

In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 4,000 shares of the stock in a transaction dated Tuesday, October 17th. The stock was sold at an average price of $71.10, for a total value of $284,400.00. Following the completion of the sale, the director now directly owns 84,394 shares in the company, valued at $6,000,413.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Scott Biller sold 2,146 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $67.23, for a total value of $144,275.58. The disclosure for this sale can be found here. Over the last quarter, insiders sold 166,746 shares of company stock valued at $11,344,756. 5.43% of the stock is currently owned by company insiders.

A number of institutional investors have recently added to or reduced their stakes in AGIO. Teachers Advisors LLC raised its stake in Agios Pharmaceuticals by 2.3% in the first quarter. Teachers Advisors LLC now owns 30,258 shares of the biopharmaceutical company’s stock valued at $1,767,000 after buying an additional 666 shares during the last quarter. Aperio Group LLC purchased a new position in shares of Agios Pharmaceuticals in the second quarter worth about $206,000. Public Employees Retirement Association of Colorado raised its stake in shares of Agios Pharmaceuticals by 5.2% in the second quarter. Public Employees Retirement Association of Colorado now owns 6,504 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 323 shares during the last quarter. Janney Montgomery Scott LLC raised its stake in shares of Agios Pharmaceuticals by 9.7% in the second quarter. Janney Montgomery Scott LLC now owns 4,820 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 425 shares during the last quarter. Finally, Great West Life Assurance Co. Can raised its stake in shares of Agios Pharmaceuticals by 84.6% in the second quarter. Great West Life Assurance Co. Can now owns 5,543 shares of the biopharmaceutical company’s stock worth $285,000 after purchasing an additional 2,541 shares during the last quarter. Institutional investors own 94.38% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Canaccord Genuity Analysts Give Agios Pharmaceuticals (AGIO) a $90.00 Price Target” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/12/agios-pharmaceuticals-agio-stock-rating-reaffirmed-by-canaccord-genuity.html.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.